RxDoctor Payments Data

Charles Baten, MD

Internal Medicine · Bradenton, FLNPI 1609840032

Payments from drug & device makers

$666in general payments, 2019–2025

Across 16 payments — averaging $41.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$165
  • Novo Nordisk$141
  • Osprey Medical Inc$135
  • Exact Sciences$89
  • Johnson & Johnson$69
  • AbbVie$50
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Silk Road Medical, Inc.1$165
Novo Nordisk2$141
Osprey Medical Inc6$135
Exact Sciences3$89
Johnson & Johnson1$69
AbbVie2$50
Phathom Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$666 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$272,686
Medicare patients
666
Services billed
7,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$76,618
JanuviaSitagliptin Phosphate50$59,642
OzempicSemaglutide45$47,955
JardianceEmpagliflozin20$32,259
MyrbetriqMirabegron24$23,040
XareltoRivaroxaban17$22,865
FarxigaDapagliflozin Propanediol16$22,372
MounjaroTirzepatide14$18,805
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,869
TradjentaLinagliptin12$8,711
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,565
LamictalLamotrigine11$7,392
Omeprazole535$6,534
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$5,870
Atorvastatin Calcium659$5,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$141$47,95545 claims
Johnson & JohnsonXarelto$69$22,86517 claims
AbbVieSynthroid$50$5,46454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →